Cancer risk prediction models: a workshop on development, evaluation, and application.

Cancer researchers, clinicians, and the public are increasingly interested in statistical models designed to predict the occurrence of cancer. As the number and sophistication of cancer risk prediction models have grown, so too has interest in ensuring that they are appropriately applied, correctly developed, and rigorously evaluated. On May 20-21, 2004, the National Cancer Institute sponsored a workshop in which experts identified strengths and limitations of cancer and genetic susceptibility prediction models that were currently in use and under development and explored methodologic issues related to their development, evaluation, and validation. Participants also identified research priorities and resources in the areas of 1) revising existing breast cancer risk assessment models and developing new models, 2) encouraging the development of new risk models, 3) obtaining data to develop more accurate risk models, 4) supporting validation mechanisms and resources, 5) strengthening model development efforts and encouraging coordination, and 6) promoting effective cancer risk communication and decision-making.

[1]  D. Easton,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.

[2]  N. Risch,et al.  The calculation of breast cancer risk for women with a first degree family history of ovarian cancer , 1993, Breast Cancer Research and Treatment.

[3]  W. Willett,et al.  Harvard Report on Cancer Prevention Volume 4: Harvard Cancer Risk Index , 2004, Cancer Causes & Control.

[4]  David F Ransohoff,et al.  Using Risk for Advanced Proximal Colonic Neoplasia To Tailor Endoscopic Screening for Colorectal Cancer , 2003, Annals of Internal Medicine.

[5]  W. E. Hoogendoorn,et al.  Modeling familial clustered breast cancer using published data. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  S. Fisher,et al.  Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA) , 2003, Breast Cancer Research.

[7]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[8]  Sowmya R. Rao,et al.  Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. , 2003, Journal of the National Cancer Institute.

[9]  J. Hopper,et al.  A simple tool for identifying unaffected women at a moderately increased or potentially high risk of breast cancer based on their family history. , 2003, Breast.

[10]  P. Pharoah,et al.  Prediction of pathogenic mutations in patients with early-onset breast cancer by family history , 2003, The Lancet.

[11]  C. Begg,et al.  Variations in lung cancer risk among smokers. , 2003, Journal of the National Cancer Institute.

[12]  A. Oshima,et al.  Estimation of individualized probabilities of developing breast cancer for Japanese women , 2003, Breast cancer.

[13]  S. Selvachandran,et al.  Prediction of colorectal cancer by a patient consultation questionnaire and scoring system: a prospective study , 2002, The Lancet.

[14]  Giovanni Parmigiani,et al.  BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Swindle,et al.  Nomograms and instruments for the initial prostate evaluation: the ability to estimate the likelihood of identifying prostate cancer. , 2002, Seminars in urologic oncology.

[16]  Sean V Tavtigian,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Benítez,et al.  Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: Implications for genetic testing , 2002, International journal of cancer.

[18]  N E Day,et al.  A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes , 2002, British Journal of Cancer.

[19]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[20]  H. Nevanlinna,et al.  A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families , 2001, British Journal of Cancer.

[21]  G. Colditz,et al.  Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. , 2000, American journal of epidemiology.

[22]  N. Carson,et al.  A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center , 2000, Clinical genetics.

[23]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[24]  M. Kattan,et al.  Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. , 1999, Urology.

[25]  E Graf,et al.  Assessment and comparison of prognostic classification schemes for survival data. , 1999, Statistics in medicine.

[26]  J Benichou,et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.

[27]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[28]  S Wacholder,et al.  The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. , 1999, American journal of human genetics.

[29]  M. Diefenbach,et al.  Prostate Cancer Risk Assessment Program , 1999 .

[30]  M. Diefenbach,et al.  Prostate cancer risk assessment program. A model for the early detection of prostate cancer. , 1999, Oncology.

[31]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[32]  A. Zwinderman,et al.  Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. , 1998, The New England journal of medicine.

[33]  S. Cummings,et al.  Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S M Grundy,et al.  Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. , 1998, Circulation.

[35]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[36]  I. Thompson,et al.  Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test. , 1997, Urology.

[37]  K Offit,et al.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. , 1997, JAMA.

[38]  F. Couch,et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.

[39]  G A Colditz,et al.  Nurses' health study: log-incidence mathematical model of breast cancer incidence. , 1996, Journal of the National Cancer Institute.

[40]  A. Whittemore,et al.  Rates and Risks of Ovarian Cancer in Subgroups of White Women in the United States , 1994, Obstetrics and gynecology.

[41]  N. Risch,et al.  Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994 .

[42]  R. Thompson,et al.  Revisions in the risk‐based breast cancer screening program at group health cooperative , 1990, Cancer.

[43]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[44]  M. Badzioch,et al.  RISK OF FAMILIAL BREAST CANCER , 1984, The Lancet.

[45]  M. King,et al.  PRACTICAL GUIDE FOR ESTIMATING RISK FOR FAMILIAL BREAST CANCER , 1983, The Lancet.

[46]  W. Kannel,et al.  A general cardiovascular risk profile: the Framingham Study. , 1976, The American journal of cardiology.